ClinConnect ClinConnect Logo
Search / Trial NCT06698341

UNdeRstAnding Novel Variants in AcutE MyocardiaL Infarction in Young Adults

Launched by NATIONAL HEART CENTRE SINGAPORE · Nov 18, 2024

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

The clinical trial titled "UNdeRstAnding Novel Variants in AcutE MyocardiaL Infarction in Young Adults" is studying why some young adults (under 60 years old) experience heart attacks, even when they don’t have common risk factors like high blood pressure or diabetes. Researchers are using advanced technologies to look closely at genes and other biological factors to find out what might lead to these heart attacks. This study aims to discover new ways to prevent heart disease and improve treatments for those affected.

To join the trial, participants need to be at least 21 years old and either under 50 years old or between 51 and 60 years old with only a couple of risk factors (excluding diabetes) at the time of their heart attack. Participants must be willing to provide consent and attend study visits. Those who are of Chinese, Malay, or Indian descent are eligible, but certain medical conditions and pregnancy may exclude others. If you join the study, you will help researchers learn more about heart disease in young adults, which could lead to better prevention and treatment strategies in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Adult \>21 years old.
  • 2. Age ≤50 years old irrespective of the presence of CV risk factors\* at the time of myocardial infarction OR Age 51-60 years old with no more than 2 CV risk factor\* at the time of myocardial infarction, excluding diabetes mellitus
  • 3. Able to provide informed consent.
  • 4. Patients who are willing and able to comply with the study visit and procedures.
  • 5. Prior type 1 myocardial infarction with angiographically/CT documented significant stenosis of ≥50% in LM or ≥70% in major epicardial/branch vessel (e.g. LAD, LCX, RCA).
  • 6. Patients who are from the three main races (Chinese, Malay, Indian). Race is self-identified by patient.
  • Hypertension, hyperlipidemia, diabetes mellitus, obesity, current smoker
  • Exclusion Criteria:
  • 1. Known familial hypercholesterolaemia, known vasculitides, end-stage renal disease and congenital heart disease.
  • 2. Prior PAD and Stroke
  • 3. Female patients who are pregnant
  • 4. Patients who are non-Asian

About National Heart Centre Singapore

The National Heart Centre Singapore (NHCS) is a leading institution dedicated to advancing cardiovascular care and research in Singapore and the Asia-Pacific region. As a premier clinical trial sponsor, NHCS is committed to improving heart health through innovative research and clinical excellence. The center specializes in a wide range of cardiovascular conditions, leveraging cutting-edge technology and a multidisciplinary approach to develop and evaluate new therapies. With a strong emphasis on patient-centered care, NHCS collaborates with various stakeholders to enhance clinical outcomes and contribute to the global body of cardiovascular knowledge.

Locations

Singapore, , Singapore

Patients applied

0 patients applied

Trial Officials

Jonathan Yap

Principal Investigator

National Heart Centre Singapore

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported